Pharmaceutical Business Review
Return to: PBR Home | Suppliers

NSF International White Papers

NSF International

Data Integrity A Closer Look Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016 by FDA, MHRA, EMA PIC/S and the WHO and yet companies continue to grapple with data integrity issues.
View white paper
Hierarchy For Capa Effectiveness Have you ever reviewed an investigation report and wondered whether the proposed corrective and preventive action (CAPA) would be effective? Sometimes, we shrug our shoulders and say, “At least they put something in place”. We all know that the FDA expects us to include an effectiveness check, but do we have enough guidance to make these checks meaningful? NSF suggests that you consider these three questions: 1. What will you measure? 2. When will you measure it? 3. What is your acceptance standard?
View white paper
Is Fear of Risk Your Biggest Risk? In this white paper, NSF International's Martin Lush gives his insights into the pharmaceutical industry's relationship with risk. It includes five steps to help you become risk smart.
View white paper
Risk Assessment: A Closer Look NSF International’s Andy Barnett takes a deeper look into ICH Q9, Quality Risk Management, with particular focus on the failure mode and effects analysis tool for risk management.
View white paper
Aging Facilities Aging facilities is a trendy catchphrase that has taken hold in the biopharmaceutical industry. This white paper by NSF International’s Nicholas Markel provides a few questions to determine if you have an aging facility as well as how to address any issues you may have.
View white paper
NSF: Global Selection Considerations for CMO When Conducting Due Diligence Deciding to use a CMO requires a thorough due diligence exercise conducted both as desktop and on-site reviews. This NSF white paper by Maxine Fritz provides the fundamental factors to consider when engaging and deciding on a CMO.
View white paper
NSF: Time To Move Beyond Mediocre CAPAs and Make Them More Effective Have you ever wondered why some of your CAPAs fail to achieve the desired improvement? Wouldn’t it be nice if there were a way to evaluate the CAPA before you implement it? NSF proposes the use of our CAPA hierarchy, which will help investigators select a CAPA that is most likely to deliver the desired outcome. Read the white paper for more information on the hierarchy and find out how else to use it.
View white paper
Do you have a robust and compliant CAPA System? Pharma biotech companies around the globe are struggling to juggle numerous priorities and challenges. One of their biggest struggles is to effectively manage CAPAs.
View white paper
How to write to Regulatory Agencies when things go wrong Your essential guidance on what to do next after you receive a less than positive regulator's audit report.
View white paper
NSF asks why Annex 1 is Important to you This white paper details the key reasons for the revision to EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. It outlines what you should be asking yourself regardless of the dosage form you are responsible for. It also includes a simple tool to assess the impact on your organization when there is a regulatory change.
View white paper
Heightened FDA Enforcement for Sterility Issuesin Pharma Biotech with NSF NSF analysed all of the warning letters issued to pharma and biologic manufacturers for sterility issues since 2015. This white paper provides detailed insight into our analysis. It includes relative charts and a table with a summary of the regulations cited by the FDA as well as recommendations for closing your compliance gaps.
View white paper
NSF: Essential Rules When Investigating GMP Deviations During Sterile Processing This white paper by John Johnson outlines the key attributes to consider during sterile products manufacturing. It also details five key non-negotiables for investigating pharmaceutical GMP deviations or deficiencies in sterile processing.
View white paper
NSF Explains the Points to Consider when Auditing a Terminally Sterilised Drug Product When conducting an audit of the terminally sterilized pharmaceutical product process, the essential checklist outlined in this white paper by Maxine Fritz will help.
View white paper
NSF - Site Director: KPIs Should Look Forward as well as Measure Results A Site Director expresses his views on how to use KPIs most productively.
View white paper
NSF asks a Production Director for their views on moving forward with KPIs KPIs and the Production Director: Select Fewer, More Significant KPIs and Set Goals for Your Metrics
View white paper
NSF determines what KPIs mean for Employees KPIs and Employees: Involve Us Upfront and Let Us Help Define Relevant Measures
View white paper
NSF asks ex-MHRA Inspector about the Importance of KPIs and gets Interesting Results KPIs and the Regulator: I’m Looking for Quality Metrics, Management Review and Continual Improvement.
View white paper
Tech Talk: Changing GMP Behaviours with NSF Most people are content sticking with what they know and their tried and tested habits. It’s easy. To get people to think and act differently (a painful process for most), you have to provide them with the motivation.
View white paper
NSF: KPIs and the Head of Corporate Quality: KPIs Are Essential for a Successful Product Release What are your views on KPIs? Essential or a necessary evil? “They are absolutely essential, providing they are good! I remember during a regulatory inspection I was asked every QP’s most feared question: How do you know everything is in control before you release product?
View white paper
NSF: Learn from a Fabulously Successful GMP Remediation Program This White Paper describes a remediation program that appeared at first to be impossibly daunting, expensive and unattainable. The company had received a range of critical and major GMP deficiencies from the UK regulatory body, MHRA, and was facing a referral to MHRA’s Inspection Action Group. Manufacturing had to be suspended pending a risk assessment of the non-compliances; evaluating the effect of the non-compliances in terms of risks of misbranding and adulteration of the products. Shifts were cancelled, the supply chain was suspended and an urgent remediation program begun.
View white paper
NSF: Remediation of Pharma Quality Systems – It’s All About the People Much of NSF Pharma Biotech Consulting’s work involves helping companies remediate flawed quality systems. This is usually done as a result of threatened or actual enforcement action by regulatory agencies. In these circumstances, companies are desperate and willing to do ‘whatever it takes’ without a full understanding of what that means. While expansive in concept, ‘whatever it takes,’ for many, means simply deploying internal and external resources to design and document a new quality management system. This is a significant commitment by management in resources, but unless the cause (how did this happen?) is also considered, the effort is doomed to fail.
View white paper
Brexit Implications for UK Pharmaceutical Administration with NSF With the historic vote by the UK to leave the European Union we have been asked by many of our clients and colleagues “What will the vote to leave the EU (Brexit) mean for pharmaceutical quality management and the role of the Qualified Person (QP)?” The only thing that is certain is that we are facing at least two, and probably more, years of unprecedented uncertainty.
View white paper
NSF: Techniques to tackle our current Complexity Crisis Over the last 30 years we have seen levels of complexity in the pharma industry increase dramatically. It’s getting close to a crisis point. Although some complexity is triggered by events we can’t influence (regulations, globalization and the like), most is created by choice.
View white paper
What NSF’s Remediation Projects Are Saying About the Industry NSF Pharma Biotech Consulting is in a unique position in that our team is regularly and intimately involved in a range of GMP remediation projects across the world and across all dosage forms. Offering companies a different perspective on current industry thinking or for us to review and verify that the proposed CAPA will be effective across the full range of key attributes. These attributes include cost, timeframe, GMP compliance, sustainability, simplicity and ease of presentation to clients and regulators.
View white paper
NSF: What Works and What Doesn’t When Changing your Quality Culture and Improving GMP Behaviors Ever wondered why 70% of change initiatives fail, or why 95% of New Year’s resolutions are forgotten by February? The same reason traditional training methods have little impact on workplace behaviors, and why the “carrot and stick” (reward vs. punishment) approach to changing behaviors doesn’t work. In this article, we detail how to really change your quality culture and improve GMP behaviors.
View white paper
So How Is NSF Moving E.A.S.T.? How does an organization stand out from the crowd in the global marketplace, where businesses vie for attention and custom, and a multitude of choices exist in every transaction? Communication that seeks a change in an organization has to be Easy, Attractive, Social, Timely (E.A.S.T)
View white paper